David Pound

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Interim Analysis, Metabolic Associated Steatohepatitis, Hepatology +7

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

Kris V. Kowdley, Stuart C. Gordon, K. Rajender Reddy et al. · New England Journal of Medicine · 2014 · 1.1K citations · Full text

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

Paul Y. Kwo, Eric Lawitz, Jonathan McCone et al. · The Lancet · 2010 · 703 citations · Full text

Hepatology, Hepatitis C, Viral Hepatitis +10

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 438 citations

Fibrosis, Hepatology, Liver Physiology +9

Colonic neoplasia in asymptomatic persons with negative fecal occult blood tests: influence of age, gender, and family history.

Douglas K. Rex, Glen A. Lehman, Thomas M. Ulbright et al. · PubMed · 1993 · 351 citations

Epidemiology Of Cancer, Gastroenterology, Gynecology +16